☆ 4.6 Review

Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

Leukemic stem cells and therapy resistance in acute myeloid leukemia

Patrick Stelmach et al.

Summary: A major challenge in treating acute myeloid leukemia (AML) is the presence of therapy-resistant cells, known as leukemic stem cells (LSC), which can contribute to relapse after achieving remission. LSC display significant plasticity and can develop mechanisms to resist treatment, making them difficult to target with chemotherapy. The combination of venetoclax and azacitidine shows promise in targeting AML LSC, but it is still unclear which patients would benefit most from this treatment and how to overcome resistance mechanisms. Clinical trials are underway to investigate LSC susceptibility to first-line therapies and better understand the complex nature of AML. This review discusses the biology of LSC, resistance mechanisms, potential vulnerabilities, and ongoing clinical trial activities related to LSC-targeted therapies.

HAEMATOLOGICA (2023)

添加到收藏夹

Article Oncology

Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort

Naveen Premnath et al.

Summary: Vitamin C is crucial for epigenetic regulation and its deficiency can promote leukemogenesis. Limited studies have investigated vitamin C levels in patients with myeloid malignancies. In this study, we retrospectively analyzed a prospective cohort and found that 17% of patients had low vitamin C levels, which were associated with younger age at diagnosis, increased risk of acute myeloid leukemia, and ASXL1 mutations. Further multi-institutional studies are needed to understand the relevance and potential benefits of vitamin C supplementation in myeloid neoplasms.

LEUKEMIA RESEARCH (2023)

添加到收藏夹

Review Hematology

Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.

Aimee Merino et al.

Summary: Natural Killer (NK) cells show promise in treating hematologic malignancies. Adoptively transferred allogeneic NK cells have demonstrated safety and minimal risk of complications. Unlike genetically altered T cells, HLA mis-matched NK cells can be used without the risk of graft vs host disease (GVHD), making them ideal for off-the-shelf products. Enhancing NK cell targeting and function in the tumor microenvironment is crucial for the future of NK cell therapy.

BLOOD REVIEWS (2023)

添加到收藏夹

Review Oncology

Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia

Jiasheng Wang et al.

Summary: The search for effective therapies for the highly heterogenous disease acute myeloid leukemia (AML) has been difficult. However, sophisticated molecular studies have identified defects within AML cells that can be targeted using small molecule agents, leading to the development of several FDA-approved medications. Additionally, emerging small molecules offer new treatment options for AML, and the combination of these agents with cytotoxic drugs and immunotherapy may further improve outcomes.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)

添加到收藏夹

Article Engineering, Biomedical

Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia

Yifeng Xia et al.

Summary: This study found that transferrin-guided polymersomes (TPs) significantly enhance the targetability, potency, and safety of the PLK1 inhibitor volasertib (Vol) against acute myeloid leukemia (AML). Vol-loaded TPs (TPVol) exhibited the highest cellular uptake, effective down-regulation of p-PLK1, p-PTEN, and p-AKT, and superior apoptotic activity compared to free Vol in leukemic cells. TPVol showed 6-fold higher AUC and notable accumulation in AML-residing bone marrow after intravenous injection. In an orthotopic leukemic model, TPVol significantly reduced leukemic cell proportions in peripheral blood, bone marrow, liver, and spleen, enhanced mouse survival rate, and impeded bone loss. This transferrin-guided nano-delivery strategy appears to be an interesting approach for the development of novel treatments for AML.

BIOACTIVE MATERIALS (2023)

添加到收藏夹

Article Oncology

Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Eric Wang et al.

Summary: Therapy resistance is a major challenge in cancer treatment. Through CRISPR-Cas9 screens, we identified the importance of RNA splicing factors in determining response to BCL2 inhibitor venetoclax in acute myeloid leukemia. Inhibition of splicing kinases CLKs and DYRKs can overcome resistance to BCL2 inhibition by inducing aberrant splicing of key factors.

CANCER CELL (2023)

添加到收藏夹

Article Hematology

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Amer M. Zeidan et al.

Summary: Y CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRP alpha interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. The phase 1 clinical trial in patients with relapsed/refractory AML or high-risk MDS showed that CC-90002 led to mostly adverse events such as diarrhea and thrombocytopenia, with no objective responses observed. Further studies are needed to understand the lack of monotherapy activity and the development of anti-drug antibodies in this treatment.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Article Cell & Tissue Engineering

The microbiota regulates hematopoietic stem cell fate decisions by controlling iron availability in bone marrow

Dachuan Zhang et al.

Summary: This study reveals that the microbiota regulates hematopoietic stem cells (HSCs) self-renewal and differentiation by modulating local iron availability in the bone marrow. Microbiota depletion enhances HSC self-renewal but compromises differentiation under stress conditions. The interplay between the microbiota, macrophages, and iron is essential for regulating critical HSC fate decisions.

CELL STEM CELL (2022)

添加到收藏夹

Article Oncology

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein et al.

Summary: This phase I study investigated the recommended dose for expansion of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. The study found recommended doses/regimens for future combination studies. Patients with solid tumors and hematologic malignancies differed in terms of treatment-related adverse events.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Warren Fiskus et al.

Summary: Treatment with Menin inhibitor disrupts the interaction between Menin and MLL1 or MLL1-fusion protein, inhibiting AML cell survival and inducing differentiation. Combining Menin inhibitor with other drugs enhances the therapeutic efficacy against AML cells.

BLOOD CANCER JOURNAL (2022)

添加到收藏夹

Article Hematology

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia

Dan Cojocari et al.

Summary: Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 inhibitor, venetoclax (VEN) is used in combination with azacitidine (AZA), a DNA-methyltransferase inhibitor (DNMTi), to treat patients with AML. Despite promising response rates to VEN/AZA, resistance to the agent is common. One identified mechanism of resistance is the upregulation of myeloid cell leukemia-1 protein (MCL1). Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1. We demonstrate that PEV/AZA combination induces NOXA to a greater degree than either PEV or AZA alone, which enhances VEN-mediated apoptosis. Herein, using AML cell lines and primary AML patient samples ex vivo, including in cells with genetic alterations linked to treatment resistance, we demonstrate robust activity of the PEV/VEN/AZA triplet. These findings were corroborated in preclinical systemic engrafted models of AML. Collectively, these results provide rational for combining PEV/VEN/AZA as a novel therapeutic approach in overcoming AML resistance in current therapies.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Amer M. Zeidan et al.

Summary: Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. However, in this study, the combination of durvalumab and azacitidine did not improve clinical efficacy compared with azacitidine alone in older patients with acute myeloid leukemia.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Oncology

Emerging CAR T Cell Strategies for the Treatment of AML

Paresh Vishwasrao et al.

Summary: CAR-T cell therapy is a promising cancer treatment method, but it also brings about some immune-related toxicities. Impressive results have been achieved in treating B cell hematological malignancies, but further research is needed for other hematological malignancies. This article summarizes the findings from preclinical and human studies of CAR-T cell therapy and discusses new treatment targets.

CANCERS (2022)

添加到收藏夹

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

添加到收藏夹

Article Oncology

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

Asmita Mishra et al.

Summary: This study evaluated the efficacy and safety of Eprenetapopt combined with azacitidine as maintenance therapy after HCT in patients with mTP53 AML and MDS. The results showed that this treatment regimen was well tolerated and achieved encouraging RFS and OS outcomes in this high-risk population.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance.

Zhuoer Xie et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Ades et al.

Summary: The study compared the efficacy of pevonedistat+azacitidine to azacitidine monotherapy in patients with newly diagnosed higher-risk myelodysplastic syndromes and found that in certain patient populations, the new treatment may yield better clinical outcomes, while continued therapy could potentially improve survival.

BLOOD ADVANCES (2022)

添加到收藏夹

Meeting Abstract Hematology

Targeting PLK1 As a Novel Strategy for Acute Myeloid Leukemias with Fanconi Anemia Pathway Mutations

Aditya S. Sheth et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Michele Mayo et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin Watts et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa et al.

BLOOD (2022)

添加到收藏夹

Meeting Abstract Hematology

Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features

Sameem Abedin et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy et al.

Summary: This study presents the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML, showing clinical benefits in PIF/ER patients and encouraging evidence of activity. Flotetuzumab represents an innovative experimental approach associated with acceptable safety.

BLOOD (2021)

添加到收藏夹

Article Oncology

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine plus Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia

Joshua F. Zeidner et al.

Summary: Alvocidib, when combined with 7+3 induction therapy, shows promising clinical activity in newly diagnosed acute myeloid leukemia patients, indicating the potential for further investigation of Alvocidib combinations in this population.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Hematology

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A. Sallman et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HRMDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner et al.

BLOOD (2021)

添加到收藏夹

Meeting Abstract Hematology

Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study

Nicholas J. Short et al.

BLOOD (2021)

添加到收藏夹

Article Oncology

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)

Thomas Cluzeau et al.

Summary: The combination of Eprenetapopt with AZA showed potentially higher overall response rate (ORR) and complete remission (CR) rate, as well as longer overall survival (OS) in untreated high-risk TP53m MDS and AML patients, with main treatment-related adverse events being febrile neutropenia and neurologic adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.

Hui Zhang et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Qingya Cui et al.

Summary: The study demonstrated the potential efficacy and safety of CD38-targeted CAR-T cells in treating relapsed AML patients by eliminating CD38 positive blasts without off-target effects, although the risk of relapse still exists.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma et al.

Summary: H3B-8800 treatment was associated with mostly low-grade treatment-related adverse events and induced red blood cell transfusion independence in a subset of MDS patients.

LEUKEMIA (2021)

添加到收藏夹

Article Medicine, General & Internal

Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

Joseph M. Unger et al.

Summary: Clinical trial enrollments decreased during the full year of the COVID-19 pandemic, with reductions primarily seen in cancer control and prevention trials. However, there was not strong evidence of enrollment reductions in treatment trials, indicating that clinical research quickly adapted to enrolling and treating patients on protocols during the pandemic.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Hematology

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Hartmut Dohner et al.

Summary: This phase 3 trial did not demonstrate a survival benefit with the polo-like kinase inhibitor volasertib combined with low-dose cytarabine in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy, potentially due to increased early mortality in the volasertib group from myelosuppression and infections.

HEMASPHERE (2021)

添加到收藏夹

Article Hematology

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia

Nabih Maslah et al.

HAEMATOLOGICA (2020)

添加到收藏夹

Editorial Material Hematology

A bispecific approach to improving CAR T cells in AML

Naval Daver

BLOOD (2020)

添加到收藏夹

Article Oncology

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

Geoffrey L. Uy et al.

INVESTIGATIONAL NEW DRUGS (2020)

添加到收藏夹

Letter Oncology

Biomarkers for RBM39 degradation in acute myeloid leukemia

David Hsiehchen et al.

LEUKEMIA (2020)

添加到收藏夹

Article Oncology

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

Farhad Ravandi et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Hematology

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

David A. Sallman et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations

Hongzhi Miao et al.

BLOOD (2020)

添加到收藏夹

Article Oncology

Characterization of a Novel FLT3 BITE Molecule for the Treatment of Acute Myeloid Leukemia

Bettina Brauchle et al.

MOLECULAR CANCER THERAPEUTICS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Carsten Riether et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Hematology

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Jayakumar Vadakekolathu et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Meeting Abstract Hematology

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi et al.

BLOOD (2020)

添加到收藏夹

Review Oncology

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Hao Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Hematology

The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

C. K. Brierley et al.

TRANSFUSION (2019)

添加到收藏夹

Article Oncology

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation

Jia Yi Fong et al.

CANCER CELL (2019)

添加到收藏夹

Meeting Abstract Hematology

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Justin M. Watts et al.

BLOOD (2019)

添加到收藏夹

Meeting Abstract Hematology

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Jennifer A. Foltz et al.

BLOOD (2019)

添加到收藏夹

Article Oncology

Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes

Linn Gillberg et al.

CLINICAL EPIGENETICS (2019)

添加到收藏夹

Article Oncology

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Patrick Williams et al.

CANCER (2019)

添加到收藏夹

Meeting Abstract Hematology

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Naval G. Daver et al.

BLOOD (2019)

添加到收藏夹

Meeting Abstract Hematology

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion y Subklewe et al.

BLOOD (2019)

添加到收藏夹

Meeting Abstract Hematology

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt et al.

BLOOD (2019)

添加到收藏夹

Article Oncology

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Hematology

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition

Celine Moison et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Article Hematology

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Ronan T. Swords et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Rita Assi et al.

CANCER (2018)

添加到收藏夹

Article Oncology

The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia

Huihui Zhao et al.

LEUKEMIA RESEARCH (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host

Marlies Meisel et al.

NATURE (2018)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety

Xingjian Gu et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

添加到收藏夹

Meeting Abstract Hematology

First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

Fang Liu et al.

BLOOD (2018)

添加到收藏夹

Meeting Abstract Hematology

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

James Y. Chen et al.

BLOOD (2018)

添加到收藏夹

Meeting Abstract Hematology

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A. Sallman et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

C. Dafflon et al.

LEUKEMIA (2017)

添加到收藏夹

Review Virology

Redefining Memory: Building the Case for Adaptive NK Cells

Silke Paust et al.

JOURNAL OF VIROLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Ascorbate regulates haematopoietic stem cell function and leukaemogenesis

Michalis Agathocleous et al.

NATURE (2017)

添加到收藏夹

Article Oncology

Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation

Yan-Fang Tao et al.

ONCOLOGY REPORTS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

Ting Han et al.

SCIENCE (2017)

添加到收藏夹

Meeting Abstract Oncology

CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).

Eunice S. Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML

Fabiana Perna et al.

CANCER CELL (2017)

添加到收藏夹

Article Oncology

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Daniel A. Vallera et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia

Michael W. M. Kuhn et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Hematology

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

David P. Steensma et al.

BLOOD (2015)

添加到收藏夹

Article Oncology

Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo

Dmitry Borkin et al.

CANCER CELL (2015)

添加到收藏夹

Article Hematology

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Joshua F. Zeidner et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Review Oncology

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Joshua F. Zeidner et al.

LEUKEMIA RESEARCH (2015)

添加到收藏夹

Article Oncology

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

Andreas D. Orskov et al.

ONCOTARGET (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis

Shiv Kumar et al.

BIOMED RESEARCH INTERNATIONAL (2015)

添加到收藏夹

Article Hematology

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Joshua F. Zeidner et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

Jie Liu et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

Sophia Adamia et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Hematology

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Francis Mussai et al.

BLOOD (2013)

添加到收藏夹

Review Cell Biology

Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response

H. Christian Reinhardt et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)

添加到收藏夹

Article Oncology

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Michelle K. Gleason et al.

MOLECULAR CANCER THERAPEUTICS (2012)

添加到收藏夹

Article Hematology

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

Ronan T. Swords et al.

BLOOD (2010)

添加到收藏夹

Article Hematology

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

Annelies G. Renner et al.

BLOOD (2009)

添加到收藏夹

Article Oncology

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

Jeremy M. R. Lambert et al.

CANCER CELL (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

Siddhartha Jaiswal et al.

CELL (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Ravindra Majeti et al.

CELL (2009)

添加到收藏夹

Article Multidisciplinary Sciences

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Teresa A. Soucy et al.

NATURE (2009)

添加到收藏夹

Article Oncology

Interaction of MLL amino terminal sequences with menin is required for transformation

Corrado Caslini et al.

CANCER RESEARCH (2007)

添加到收藏夹

Article Multidisciplinary Sciences

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression

YX Chen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

添加到收藏夹

Article Multidisciplinary Sciences

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

LT Vassilev et al.

SCIENCE (2004)

添加到收藏夹

Review Cell Biology

Polo-like kinases and the orchestration of cell division

FA Barr et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)

添加到收藏夹

Article Multidisciplinary Sciences

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

L Ruggeri et al.

SCIENCE (2002)

添加到收藏夹

Article Immunology

CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells

BR Blazar et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.